comprehensive -WSS

comprehensive

author：explore 2025-08-23 08:56:48 - browse：5243

Principal Deputy FDA Commissioner Janet Woodcock Stefani Reynolds/The New York Times via AP

WASHINGTON — Principal Deputy FDA Commissioner Janet Woodcock will retire early next year from the Food and Drug Administration after helping steer the agency through an historic period of medical advances during nearly four decades in key leadership positions, she confirmed to STAT Thursday.

Woodcock, a doctor with a chemistry degree, joined FDA in 1986 at its biologics center, where she oversaw the approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis. In 1994, she was named director of the drug center, where she played a key role in guiding some of the most impactful changes to the regulation of medicine, according to Trump administration FDA Commissioner Scott Gottlieb.

Woodcock envisioned that antibody drugs would become a backbone of therapy and created a more predictable regulatory path for their review and approval, Gottlieb said. She presided over a major expansion and modernization of the generic drug program, standardizing reviews in a way that allowed the industry to become safer and more robust, and crafted the reform of over-the-counter drug reviews.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： CVS is willing to dump 10% of its Medicare Advantage members

WSS

UnitedHealth argues against case alleging wrongful AI care denials

Hottest summer in 2,000 years puts focus on extreme heat, health

Obesity drug from Roche shows promise in early study

Fertility clinic egg and embryo storage is a disaster

Abbott's new stent may help patients with peripheral artery disease

H5N1 bird flu outbreak: Second human case reported, in Michigan

knowledge

comprehensive

explore

Anesthesiologist group: stop taking Ozempic before surgery

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

DIEP, the 'gold standard' of breast reconstruction, is under threat

H5N1 virus can be tracked in retail milk, scientists say

Psychedelics group wrestles with new pharma identity

UnitedHealth argues against case alleging wrongful AI care denials

Jerome Adams on the need for new antivirals for Covid

STAT series 'Denied by AI' wins major journalism prizes

ChatGPT in medicine: STAT answers readers' burning questions

ALS treatment from Biogen, Ionis fails in study

hotspot

As H5N1 spreads in cows, experts warn against drinking raw milk

Cue Health, Covid

Investigation reveals sickle cell patients pressured into sterilizations

Biogen joins immunology wave with $1.15 billion acquisition of HI

Fentanyl is making it harder to start addiction treatment

As H5N1 spreads in cows, experts warn against drinking raw milk

leisure time

explore

focus

explore